

Dosing modifications when initiating strong or moderate CYP3A inducers^a

^aDosing recommendations are not available for the initiation of YEZTUGO in individuals already receiving strong or moderate CYP3A inducers, nor in individuals receiving the weekly oral dosage of YEZTUGO.¹

Please contact your Field Reimbursement Manager (FRM) regarding access to supplemental YEZTUGO dose(s).

Indication

YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35 kg) who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO.

Important Safety Information

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF YEZTUGO IN UNDIAGNOSED HIV-1 INFECTION

- Individuals must be tested for HIV-1 infection prior to initiating YEZTUGO, and with each subsequent injection of YEZTUGO, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of YEZTUGO by individuals with undiagnosed HIV-1 infection. Do not initiate YEZTUGO unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving YEZTUGO must transition to a complete HIV-1 treatment regimen.

Contraindications

- YEZTUGO is contraindicated in individuals with unknown or positive HIV-1 status.

Warnings and precautions

- **Comprehensive risk management:**
 - Use YEZTUGO to reduce the risk of HIV-1 acquisition as part of a comprehensive prevention strategy including adherence to the administration schedule and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs).

Please see additional Important Safety Information throughout and full [Prescribing Information](#) for YEZTUGO, including **BOXED WARNING**.

Supplemental YEZTUGO dosing for coadministration with either a strong or moderate CYP3A inducer^{1,a}



MAINTAIN scheduled injection dosing

Continue to administer **once-every-6-months** scheduled continuation dosing of YEZTUGO 927 mg subcutaneously (2 x 1.5-mL injections), plus administer supplemental doses of YEZTUGO as shown below.



ADD supplemental doses for coadministration with either a strong or moderate CYP3A inducer

Supplemental doses of YEZTUGO are recommended in addition to scheduled continuation dosing of YEZTUGO for individuals initiating therapy with either strong or moderate CYP3A inducers.

Strong CYP3A inducers may be initiated starting **at least 2 days after** YEZTUGO is first initiated.

Moderate CYP3A inducers may be started **any time after** YEZTUGO is first initiated.



AFTER STOPPING the strong or moderate CYP3A inducer, continue the **once-every-6-months** scheduled continuation injections of YEZTUGO

^aDosing recommendations are not available for the initiation of YEZTUGO in individuals already receiving strong or moderate CYP3A inducers, nor in individuals receiving the weekly oral dosage of YEZTUGO.¹

Please contact your FRM regarding access to supplemental YEZTUGO dose(s).

Important Safety Information (cont'd)

Warnings and precautions (cont'd)

• **Comprehensive risk management: (cont'd)**

- HIV-1 acquisition risk includes behavioral, biological, or epidemiologic factors including, but not limited to, condomless sex, past or present STIs, self-identified HIV risk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high-prevalence area or network. Counsel individuals on the use of other prevention methods to help reduce their risk.
- Use YEZTUGO only in individuals confirmed to be HIV-1 negative. Evaluate for current or recent signs or symptoms consistent with HIV-1 infection. Confirm HIV-1 negative status prior to initiating, prior to each subsequent injection, and as clinically appropriate.


Please see additional Important Safety Information throughout and full [Prescribing Information](#) for YEZTUGO, including **BOXED WARNING**.

yeztugo[®]
(lenacapavir) injection
463.5 mg/1.5 mL

YEZTUGO dosing schedule¹

 300-mg tablet  1.5-mL (463.5 mg) subcutaneous injection

Initiation timeline for illustrative purposes based on Prescribing Information.



Dosage: Initiation dosing (injections and tablets) followed by once-every-6-months continuation injection dosing. Tablets may be taken with or without food.

- **Initiation:** Day 1: 927 mg by subcutaneous injection (2 x 1.5-mL injections) and 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally
- **Continuation:** 927 mg by subcutaneous injection every 6 months (26 weeks) from date of last injection ±2 weeks

Important Safety Information (cont'd)

Warnings and precautions (cont'd)


- **Potential risk of resistance:**
 - There is a potential risk of developing resistance to YEZTUGO if an individual acquires HIV-1 before or when receiving YEZTUGO, or following discontinuation. HIV-1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection taking only YEZTUGO, because YEZTUGO alone is not a complete regimen for HIV-1 treatment.
 - To minimize this risk, it is essential to test before each injection and additionally as clinically appropriate. Individuals confirmed to have HIV-1 must immediately begin a complete HIV-1 treatment regimen.
 - Alternative forms of PrEP should be considered after discontinuation of YEZTUGO for those who are at continuing risk of HIV-1 acquisition and should be initiated within 28 weeks of the last YEZTUGO injection.
- **Long-acting properties and potential associated risks:**
 - Residual concentrations of YEZTUGO may remain in systemic circulation for up to 12 months or longer after the last injection.
 - Select individuals who agree to the required injection dosing schedule because nonadherence or missed doses could lead to HIV-1 acquisition and development of resistance.
- **Serious injection site reactions:** Improper administration (intradermal injection) has been associated with serious injection site reactions, including necrosis and ulcer. Only administer YEZTUGO subcutaneously.

Please see additional Important Safety Information throughout and full [Prescribing Information](#) for YEZTUGO, including **BOXED WARNING**.

yeztugo[®]
(lenacapavir) injection
463.5 mg/1.5 mL

Dosing recommendations for individuals starting a strong CYP3A inducer while receiving YEZTUGO^{1,a}

 300-mg tablet  1.5-mL (463.5 mg) subcutaneous injection



^aDosing recommendations are not available for the initiation of YEZTUGO in individuals already receiving strong CYP3A inducers, nor in individuals receiving the weekly oral dosage of YEZTUGO.¹

Initiation timeline for illustrative purposes based on Prescribing Information.

Please contact your FRM regarding access to supplemental YEZTUGO dose(s).

Important Safety Information (cont'd)

Adverse reactions

- Most common adverse reactions (≥5%) in YEZTUGO clinical trials were injection site reactions, headache, and nausea.

Drug interactions


- Strong or moderate CYP3A inducers may significantly decrease YEZTUGO concentrations. Dosage modifications are recommended when initiating these inducers.

Please see additional Important Safety Information throughout and full [Prescribing Information](#) for YEZTUGO, including **BOXED WARNING**.

yeztugo[®]
 (lenacapavir) injection
 463.5 mg/1.5 mL

Dosing recommendations for individuals starting a moderate CYP3A inducer while receiving YEZTUGO^{1,a}

 300-mg tablet  1.5-mL (463.5 mg) subcutaneous injection



^aDosing recommendations are not available for the initiation of YEZTUGO in individuals already receiving moderate CYP3A inducers, nor in individuals receiving the weekly oral dosage of YEZTUGO.¹

Initiation timeline for illustrative purposes based on Prescribing Information.

Please contact your FRM regarding access to supplemental YEZTUGO dose(s).

Important Safety Information (cont'd)

Drug interactions (cont'd)

- It is not recommended to use YEZTUGO with combined P-gp, UGT1A1, and strong CYP3A inhibitors.

Please see additional Important Safety Information throughout and full [Prescribing Information](#) for YEZTUGO, including **BOXED WARNING**.

yeztugo[®]
(lenacapavir) injection
463.5 mg/1.5 mL

yeztugo[®]
(lenacapavir) injection
463.5 mg/1.5 mL

YEZTUGO is the first-and-only PrEP option that offers in-office subcutaneous injections every 6 months (after initiation dosing)^{1,2}

YEZTUGO is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥ 35 kg) who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO.

Learn more about initiating CYP3A inducers at [YEZTUGOhcp.com/dosing-administration#dose-modifications](https://yeztugohcp.com/dosing-administration#dose-modifications)

Important Safety Information (cont'd)

Drug interactions (cont'd)

- Coadministration of YEZTUGO with sensitive substrates of CYP3A or P-gp may increase their concentrations and result in the increased risk of their adverse events. YEZTUGO may increase the exposure of drugs primarily metabolized by CYP3A initiated within 9 months after the last injection of YEZTUGO.

Dosage and administration

- **HIV screening:** Test for HIV-1 infection prior to initiating, prior to each subsequent injection, and as clinically appropriate using an approved or cleared test for the diagnosis of acute or primary HIV-1 infection.
- **Dosage:** Initiation dosing (injections and tablets) followed by once-every-6-months continuation injection dosing. Tablets may be taken with or without food.
 - **Initiation:** Day 1: 927 mg by subcutaneous injection (2 x 1.5-mL injections) and 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally.
 - **Continuation:** 927 mg by subcutaneous injection every 6 months (26 weeks) from date of last injection ± 2 weeks.
- **Anticipated delayed injections:** If scheduled 6-month injection is anticipated to be delayed by more than 2 weeks, YEZTUGO tablets may be taken on an interim basis (for up to 6 months) until injections resume. Dosage is 300 mg orally (1 x 300-mg tablet) once every 7 days. Resume continuation injections within 7 days of the last oral dose.
- **Missed injections:** If more than 28 weeks have elapsed since the last injection and YEZTUGO tablets have not been taken, restart with initiation dosing if clinically appropriate.
- Dosage modifications of YEZTUGO are recommended when initiating with strong or moderate CYP3A inducers. Consult the full Prescribing Information for recommendations.

Please see additional Important Safety Information throughout and full [Prescribing Information](#) for YEZTUGO, including **BOXED WARNING**.

References: 1. YEZTUGO. Prescribing information. Gilead Sciences, Inc.; 2025. 2. Yeztugo[®] (lenacapavir) is now the first and only FDA-approved HIV prevention option offering 6 months of protection. News release. Gilead Sciences, Inc.; June 18, 2025. Accessed July 24, 2025. <https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection>



YEZTUGO, the YEZTUGO Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks referenced herein are the property of their respective owners.
©2026 Gilead Sciences, Inc. All rights reserved. US-YTGP-0384 02/26